0000000000210439

AUTHOR

Di Maio M.

showing 3 related works from this author

Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STE…

2011

Introduction: Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence. Methods: Patients with extensive SCLC, age >70 years, and performance status 0-2 were eligible for a study looking for optimal two-drug combination of gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Gemcitabine dose was the same (1000 mg/m2, days 1-8) in all combinations. A two-stage minimax flexible design for response was applied to GemVin combination (Vin 25 mg/m2, days 1-8). For GemCar, GemCis, GemEto, a phase I-II Bayesian design was applied, looking for the optimal dose of the partner drugs. Objective response rate ≥60% and un…

OncologyMaleLung NeoplasmsDeoxycytidineCarboplatinchemistry.chemical_compoundElderlyAntineoplastic Combined Chemotherapy Protocols80 and overCarcinoma Small CellMultivariate AnalysiEtoposideEtoposidePlatinum compoundsAged 80 and overArea under the curveSCLCVinorelbinePrognosisElderly; Etoposide; Gemcitabine; Platinum compounds; SCLC; Vinorelbine; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; VinorelbineTreatment OutcomeOncologyPlatinum compoundToxicityFemalemedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiVinorelbineVinblastineDisease-Free SurvivalInternal medicinemedicineHumansAgedProportional Hazards ModelsCisplatinAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryCarcinomaSmall CellGemcitabineGemcitabineCarboplatinSurgeryLung NeoplasmchemistryMultivariate AnalysisProportional Hazards ModelQuality of LifeCisplatinbusiness
researchProduct

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: prelimi…

2006

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged 2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed…

OncologyCancer Researchendocrine system diseasesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPACLITAXELlaw.inventionPolyethylene Glycolschemistry.chemical_compoundRandomized controlled trialSTAGE-IIIlawCYCLOPHOSPHAMIDEAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsSTERICALLY STABILIZED LIPOSOMESMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyfemale genital diseases and pregnancy complicationsPaclitaxelOncologyMITO-2 randomized trialcarboplatinSURVIVALFemaleChemical and Drug Induced Liver Injurymedicine.drugAgranulocytosisResearch ArticleAdultmedicine.medical_specialtyCARCINOMAOvariectomylcsh:RC254-282Drug Administration ScheduleDrug HypersensitivityCISPLATINpreliminary resultInternal medicinemedicineGeneticsXENOGRAFTSHumansDoxorubicinParesthesianeoplasmsMETAANALYSISAgedChemotherapybusiness.industryAlopeciamedicine.diseasePHASE-IIIThrombocytopeniaCarboplatinSurgeryClinical trialchemistryDoxorubicinLiposomesFeasibility StudiesTopotecanOvarian cancerbusinessBMC Cancer
researchProduct

Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis…

2018

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

circulating tumor DNA NSCLCSettore MED/06 - Oncologia Medica
researchProduct